Want to see TSE:KNE full AI Analyst Report?
Top Page
Kane Biotech
(KNE)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.02
▼(-36.67% Downside)
Action:Reiterated
Date:09/09/26
The score is driven primarily by very weak financial performance (collapsing TTM revenue, deeply negative margins, negative equity, and sustained cash burn). Technicals add further pressure with the stock trading below major moving averages and only neutral momentum signals. Valuation provides little support due to negative earnings and no dividend yield.
Positive Factors
Biofilm technology platform
Kane Biotech is focused on a defined technology platform addressing microbial biofilms across wound care and animal health. This specialized expertise can support multiple applications and create opportunities for recurring commercialization as customers seek solutions for contamination, hygiene, and healing-related needs.
Negative Factors
Collapsing revenue base
The very low and declining trailing revenue base indicates that current commercialization has not yet produced sufficient scale. A 33.9% contraction reduces operating leverage, limits internally funded investment, and makes it harder for the company to absorb fixed costs or demonstrate durable demand across its target markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Biofilm technology platform
Kane Biotech is focused on a defined technology platform addressing microbial biofilms across wound care and animal health. This specialized expertise can support multiple applications and create opportunities for recurring commercialization as customers seek solutions for contamination, hygiene, and healing-related needs.
Read all positive factors
Kane Biotech (KNE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$4.10M
Dividend YieldN/A
Average Volume (3M)142.60K
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees32
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding205,056,560
10 Day Avg. Volume51,103
30 Day Avg. Volume142,603
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.69
Price to Sales (P/S)15.17
P/FCF Ratio-1.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kane Biotech Business Overview & Revenue Model
Company Description
Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbia...
How the Company Makes Money
Kane Biotech makes money primarily by commercializing biofilm-disruption technologies and related products, and by monetizing its intellectual property through partnered products. Key revenue streams include: (1) Product sales in animal health and...
Kane Biotech Earnings Call Summary
Earnings Call Date:Nov 28, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 26, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth driven by new product sales and service revenue streams. Strategic partnerships, regulatory approvals, and expansion into new markets were noted as positive developments. However, increased operating expenses and a decrease in cash reserves were challenges mentioned. Overall, the positive developments notably outweigh the drawbacks.Positive Updates
Significant Increase in Product Sales
Product sales for Q3 2024 were $598,000 compared to $4,000 in Q3 2023, primarily due to the first commercial sales of revyve Antimicrobial Wound Gel to the U.S. distributor ProgenaCare.
Negative Updates
Increased Operating Expenses
Total operating expenses for Q3 2024 were $1,170,000, an increase of 18% compared to $995,000 for Q3 2023, due to higher employee compensation, consulting, travel, and investor relation expenses.
Read all updates
Q3-2024 Updates
Positive
Negative
Significant Increase in Product Sales
Product sales for Q3 2024 were $598,000 compared to $4,000 in Q3 2023, primarily due to the first commercial sales of revyve Antimicrobial Wound Gel to the U.S. distributor ProgenaCare.
Read all positive updates
Company Guidance
During Kane Biotech's Q3 2024 earnings call, the guidance highlighted several key achievements and future expectations. The company recorded its first commercial sales of revyve Antimicrobial Wound Gel, contributing to product sales of $598,000 for the quarter, compared to just $4,000 in Q3 2023. Total revenue reached $1,283,000, significantly up from $27,000 in the previous year, with a gross profit of $559,000. Operating expenses increased by 18% to $1,170,000. Despite these expenses, the net loss from continuing operations decreased by 45% to $679,000. Kane Biotech is anticipating further growth, with plans for additional distribution agreements, regulatory approvals, and the launch of new products, including DispersinB Wound Gel trials and potential enhancements to their Lumixa product. Additionally, a $3 million private placement was announced to support these initiatives.Kane Biotech Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
11
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.72K | 427.87K | 2.08M | 148.98K | 156.73K | 1.61M |
| Gross Profit | -194.80K | -163.38K | 872.10K | 109.47K | 1.41M | 568.44K |
| EBITDA | -3.07M | -2.95M | -3.71M | -3.23M | -2.95M | -4.25M |
| Net Income | -2.70M | -2.72M | -3.02M | -5.03M | -3.89M | -4.60M |
Balance Sheet | ||||||
| Total Assets | 2.23M | 2.73M | 2.49M | 5.68M | 5.62M | 6.13M |
| Cash, Cash Equivalents and Short-Term Investments | 854.73K | 901.70K | 358.81K | 749.25K | 1.10M | 1.15M |
| Total Debt | 1.96M | 2.30M | 2.29M | 9.26M | 6.86M | 4.71M |
| Total Liabilities | 3.22M | 3.48M | 4.12M | 14.09M | 9.76M | 7.70M |
| Stockholders Equity | -993.86K | -746.54K | -1.63M | -10.56M | -6.52M | -3.89M |
Cash Flow | ||||||
| Free Cash Flow | -2.42M | -3.26M | -4.14M | -3.23M | -3.13M | -2.64M |
| Operating Cash Flow | -2.50M | -3.26M | -4.11M | -3.22M | -3.04M | -2.29M |
| Investing Cash Flow | -12.63K | -53.13K | 10.27M | -116.14K | -107.55K | -373.55K |
| Financing Cash Flow | 1.75M | 3.85M | -7.69M | 2.98M | 3.10M | 2.81M |
Kane Biotech Technical Analysis
Positive
0.03
Price Trends
0.02
Positive
0.03
Positive
0.03
Negative
Market Momentum
<0.01
Negative
53.92
Neutral
0.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Positive. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.92 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:KNE.
Kane Biotech Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | C$5.81M | -0.32 | -126.96% | ― | ― | -1.05% | |
42 Neutral | C$1.52M | -1.25 | -85.01% | ― | 73.76% | -108.30% | |
41 Neutral | C$4.10M | -2.05 | 273.53% | ― | ― | ― | |
29 Underperform | C$2.04M | -0.91 | 69.89% | ― | ― | ― |
* General Sector Average
TSE:KNE
Kane Biotech
0.03
-0.01
-25.00%
TSE:XRTX
XORTX Therapeutics Inc
3.19
-2.71
-45.92%
TSE:QPT
Quest Pharmatech
0.02
-0.02
-50.00%
TSE:BIOV
BioVaxys Technology
0.07
-0.23
-76.59%
TSE:MOOD
Doseology Sciences
0.19
-0.32
-63.00%
Kane Biotech Corporate Events
Business Operations and StrategyProduct-Related Announcements
Kane Biotech Expands Canadian Reach for revyve Wound Care via Ontario Medical Supply Deal
Positive
Sep 2, 2026
Kane Biotech has signed a non-exclusive distribution agreement with Ontario Medical Supply Inc. to expand the reach of its revyve advanced wound care products across Canada. Under the deal, OMS will purchase, market and support Kane’s FDA-cl...
Business Operations and StrategyFinancial Disclosures
Kane Biotech Widens Q2 Loss as It Accelerates Shift to Human Wound Care
Negative
Aug 27, 2026
Kane Biotech reported second-quarter 2026 revenue of $8,143, down from $27,997 a year earlier, reflecting its early-stage commercialization of the revyve wound care line following the exit from legacy businesses. Gross profit improved to $1,444 fr...
Business Operations and StrategyProduct-Related Announcements
Kane Biotech’s revyve Wound Care Technology Draws Military Research Interest
Positive
Aug 25, 2026
Kane Biotech announced that research on its revyve Antimicrobial Wound Gel Spray was presented at the Military Health System Research Symposium in Florida, highlighting its broad-spectrum, cavity-filling capabilities for prolonged field care and c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.